Sonoma Pharmaceuticals, Inc.
SNOA
$2.79
$0.8040.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.97M | 13.55M | 12.70M | 12.74M | 12.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.97M | 13.55M | 12.70M | 12.74M | 12.31M |
| Cost of Revenue | 8.95M | 8.33M | 7.85M | 7.99M | 7.79M |
| Gross Profit | 5.03M | 5.22M | 4.85M | 4.75M | 4.52M |
| SG&A Expenses | 7.68M | 7.51M | 7.47M | 7.58M | 7.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.44M | 17.82M | 17.33M | 17.44M | 16.75M |
| Operating Income | -4.46M | -4.28M | -4.63M | -4.70M | -4.44M |
| Income Before Tax | -3.74M | -3.74M | -4.58M | -5.03M | -5.11M |
| Income Tax Expenses | 10.00K | -56.00K | -17.00K | -196.00K | -35.00K |
| Earnings from Continuing Operations | -3.75 | -3.69 | -4.56 | -4.84 | -5.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.75M | -3.69M | -4.56M | -4.84M | -5.08M |
| EBIT | -4.46M | -4.28M | -4.63M | -4.70M | -4.44M |
| EBITDA | -4.32M | -4.12M | -4.46M | -4.53M | -4.27M |
| EPS Basic | -3.96 | -4.91 | -10.07 | -14.48 | -19.22 |
| Normalized Basic EPS | -2.51 | -3.18 | -6.04 | -8.98 | -12.09 |
| EPS Diluted | -3.96 | -4.91 | -10.07 | -14.48 | -19.22 |
| Normalized Diluted EPS | -2.51 | -3.18 | -6.04 | -8.98 | -12.09 |
| Average Basic Shares Outstanding | 4.12M | 3.20M | 2.42M | 1.82M | 1.26M |
| Average Diluted Shares Outstanding | 4.12M | 3.20M | 2.42M | 1.82M | 1.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
